Lupin Launches Generic TRICOR® Tablets

                    Lupin Launches Generic TRICOR® Tablets

  PR Newswire

  MUMBAI, India and BALTIMORE, November 20, 2012

MUMBAI, India and BALTIMORE, November 20, 2012 /PRNewswire/ --

Pharma major, Lupin Ltd., announced today that its subsidiary, Lupin
Pharmaceuticals Inc. (collectively, Lupin) has launched its Fenofibrate
Tablets, 48 mg and 145 mg strengths in the United States. Lupin had earlier
received final approval for the same from the US Food and Drug Administration
(FDA).

Lupin's Fenofibrate tablets are the AB rated generic equivalent of Abbott's
TRICOR® tablets and are indicated for Primary Hypercholesterolemia or Mixed
Dyslipidemia and Severe Hypertriglyceridemia. Abbott's TRICOR® Tablets, 48 mg
and 145 mg had sales of USD 1.26 billion as per IMS Health, June, 2012.

Commenting on the approval, Ms. Vinita Gupta, CEO, Lupin Pharmaceuticals Inc.
& Group President, Lupin Limited said, "We are very happy to bring this
product to market in the United States. Patients can be assured that they are
receiving the same high quality product they have been accustomed to at a more
affordable price."

About Lupin Limited

Headquartered in Mumbai, Lupin is an innovation led transnational
pharmaceutical company producing and developing a wide range of branded and
generic formulations and APIs. The Company is a significant player in the
Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and
NSAID space and holds global leadership positions in the Anti-TB and
Cephalosporin segment.

Lupin is the 5th largest and fastest growing generics player in the US (5.1%
market share by prescriptions, IMS Health) and the 3rd largest Indian
pharmaceutical company by sales. The Company is also the fastest growing top
10 generic pharmaceutical players in Japan and South Africa (IMS). For the
financial year ended March 2012, Lupin's Consolidated Total Income and Profit
after Tax were Rs. 70,972 million (USD 1.49 billion) and Rs. 8,676 million
(USD 182 million) respectively. Please visit http://www.lupinworld.com for
more information.

Lupin Pharmaceuticals, Inc. is the wholly owned U.S. subsidiary of Lupin
Limited.Headquartered in Baltimore, Maryland, Lupin Pharmaceuticals, Inc. is
dedicated to delivering high-quality, affordable generic medicines and branded
formulations trusted by healthcare professionals and patients across
geographies. For more information, visit http://www.lupinpharmaceuticals.com .

Safe Harbor Statement

*Tricor® is a registered trademark of Abbott Laboratories

For further information or queries please contact - Shamsher Gorawara Head -
Corporate Communications Lupin Limited: Ph: +91-98-20-338-555 Email:
shamshergorawara@lupinpharma.com
 
Press spacebar to pause and continue. Press esc to stop.